Aardvark Therapeutics, Inc.
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| – | -37.1% | +635.6% | +51.2% | |
| – | -37.1% | +615.1% | +50.9% | |
| – | -37.4% | +533.2% | -23.7% | |
| – | -38.0% | +637.4% | +49.4% | |
| – | +1.5% | +191.5% | -92.0% | |
| – | +132.3% | +256.5% | +114.1% | |
| – | +12.0% | +201.8% | +30.5% | |
| – | +299.6% | +122.0% | -9.8% | |
| – | – | – | – | |
| – | – | – | – | |
| – | +0.0% | +1.5% | +0.6% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.